Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets

Monoclonal antibodies specific for programmed cell death 1 (PDCD1, best known as PD-1) have been shown to mediate antineoplastic effects in follicular lymphoma patients. However, the relative proportion of intratumoral PD-1(+) T-cell subsets, in particular follicular helper T cells (which exert pro-...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Fuliang, Neelapu, Sattva S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011813/
https://www.ncbi.nlm.nih.gov/pubmed/24808975
http://dx.doi.org/10.4161/onci.28101
_version_ 1782314849849573376
author Chu, Fuliang
Neelapu, Sattva S
author_facet Chu, Fuliang
Neelapu, Sattva S
author_sort Chu, Fuliang
collection PubMed
description Monoclonal antibodies specific for programmed cell death 1 (PDCD1, best known as PD-1) have been shown to mediate antineoplastic effects in follicular lymphoma patients. However, the relative proportion of intratumoral PD-1(+) T-cell subsets, in particular follicular helper T cells (which exert pro-tumor functions) and effector T cells (which have anticancer activity), may impact clinical outcome, and should therefore be carefully considered for patient selection in this setting.
format Online
Article
Text
id pubmed-4011813
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40118132015-02-14 Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets Chu, Fuliang Neelapu, Sattva S Oncoimmunology Author's View Monoclonal antibodies specific for programmed cell death 1 (PDCD1, best known as PD-1) have been shown to mediate antineoplastic effects in follicular lymphoma patients. However, the relative proportion of intratumoral PD-1(+) T-cell subsets, in particular follicular helper T cells (which exert pro-tumor functions) and effector T cells (which have anticancer activity), may impact clinical outcome, and should therefore be carefully considered for patient selection in this setting. Landes Bioscience 2014-02-14 /pmc/articles/PMC4011813/ /pubmed/24808975 http://dx.doi.org/10.4161/onci.28101 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Chu, Fuliang
Neelapu, Sattva S
Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
title Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
title_full Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
title_fullStr Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
title_full_unstemmed Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
title_short Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
title_sort anti-pd-1 antibodies for the treatment of b-cell lymphoma: importance of pd-1(+) t-cell subsets
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011813/
https://www.ncbi.nlm.nih.gov/pubmed/24808975
http://dx.doi.org/10.4161/onci.28101
work_keys_str_mv AT chufuliang antipd1antibodiesforthetreatmentofbcelllymphomaimportanceofpd1tcellsubsets
AT neelapusattvas antipd1antibodiesforthetreatmentofbcelllymphomaimportanceofpd1tcellsubsets

Ejemplares similares